TY - JOUR
TI - Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement
AU - Stute, P.
AU - Spyropoulou, A.
AU - Karageorgiou, V.
AU - Cano, A.
AU - Bitzer, J.
AU - Ceausu, I.
AU - Chedraui, P.
AU - Durmusoglu, F.
AU - Erkkola, R.
AU - Goulis, D.G.
AU - Lindén Hirschberg, A.
AU - Kiesel, L.
AU - Lopes, P.
AU - Pines, A.
AU - Rees, M.
AU - van Trotsenburg, M.
AU - Zervas, I.
AU - Lambrinoudaki, I.
JO - Maturitas
PY - 2020
VL - 131
TODO - null
SP - 91-101
PB - Elsevier Ireland Ltd
SN - 0378-5122
TODO - 10.1016/j.maturitas.2019.11.002
TODO - antidepressant agent;  estradiol;  isoflavone derivative;  melatonin;  tibolone;  hormone, alternative medicine;  Article;  climacterium;  depression;  dietary supplement;  female;  hormonal therapy;  human;  Hypericum perforatum;  lifestyle modification;  postmenopause;  psychosocial care;  psychotherapy;  randomized controlled trial (topic);  systematic review (topic);  adult;  aged;  climacterium;  depression;  Europe;  lifestyle;  major depression;  medical society;  menopause;  middle aged;  postmenopause;  practice guideline;  psychology;  treatment outcome, Adult;  Aged;  Antidepressive Agents;  Complementary Therapies;  Depression;  Depressive Disorder, Major;  Europe;  Female;  Hormones;  Humans;  Life Style;  Menopause;  Middle Aged;  Perimenopause;  Postmenopause;  Practice Guidelines as Topic;  Societies, Medical;  Treatment Outcome
TODO - Introduction: Globally, the total number of people with depression exceeds 300 million, and the incidence rate is 70 % greater in women. The perimenopause is considered to be a time of increased risk for the development of depressive symptoms and major depressive episodes. Aim: The aim of this position statement is to provide a comprehensive model of care for the management of depressive symptoms in perimenopausal and early menopausal women, including diagnosis, treatment and follow-up. The model integrates the care provided by all those involved in the management of mild or moderate depression in midlife women. Materials and methods: Literature review and consensus of expert opinion. Summary recommendations: Awareness of depressive symptoms, early detection, standardized diagnostic procedures, personalized treatment and a suitable follow-up schedule need to be integrated into healthcare systems worldwide. Recommended treatment comprises antidepressants, psychosocial therapies and lifestyle changes. Alternative and complementary therapies, although widely used, may help with depression, but a stronger evidence base is needed. Although not approved for this indication, menopausal hormone therapy may improve depressive symptoms in peri- but not in postmenopausal women, especially in those with vasomotor symptoms. © 2019
ER -